KIT and gastrointestinal stromal tumor: After the samples were dichotomized into contrast groups according to tumor site (stomach, intestine), malignant potential (miniGIST, overt GIST), and oncogenic driver (KIT, PDGFRA, K/P WT), the transcriptome was interrogated for immune signatures by gene set enrichment analysis (GSEA), Ingenuity Pathway Analysis (IPA), and Reactome analyses.